期刊
MICROBES AND INFECTION
卷 16, 期 6, 页码 512-517出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.micinf.2014.02.011
关键词
Bacteriophage; Mouse; Podoviridae; Therapeutic; Therapy
资金
- Center for Innovative and Translational Medicine, Kochi System Glycobiology Center [24791025]
- Center of Biomembrane Functions Controlling Biological Systems, Kochi University, Kochi, Japan
- Grants-in-Aid for Scientific Research [26461504, 23591478, 24791025] Funding Source: KAKEN
Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13' was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13'. Intraperitoneal phage administration at 6 h postinfection reduced the severity of infection and rescued the infected mice. Phage S13' can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacterernia in vitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia. (C) 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据